{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'classified as normal, above normal, or below normal based on normal ranges provided by the', 'laboratory. Patients who have at least one incidence of potentially clinically significant', 'abnormalities (PCSA) during the TEAE period will be summarized. Individual listings of patients', 'with PCSA will be presented.', 'The liver function test, alanine aminotransferase (ALT) will be used to assess possible liver', 'function injure. Time to onset of the initial ALT elevation (>3ULN) will be analyzed using', 'Kaplan-Meier estimate. The normalization (to 1 ULN) of ALT will be summarized by categories', 'of elevation (3 x, 5 X, 10 X, 20 X ULN) with the following categories of normalization: never', 'normalized, normalized before permanent discontinuation of study drug, and normalized after', 'permanent discontinuation of study drug. Note that a patient will be counted only under the', 'maximum elevation category.', '11.4.3.3 Physical examination and vital signs', 'Potentially clinically significant findings observed during the TEAE observation period for vital', 'signs (including but not limited to blood pressure, heart rate, respiratory rate, etc.) will be', 'summarized by study visit. Listings of abnormal findings/values from these data as well as from', 'physical examination inclusive of body weight and height, as well as Tanner stage in paediatric', 'patients, will be presented. Change in vital signs during and immediately following IV', 'administration from preinfusion will also be summarized.', '11.4.3.4 Other safety endpoints', 'Observed measurements and changes from baseline to study time points in antialemtuzumab', 'antibody titers will be summarized using descriptive statistics.', '11.4.4 Analyses of pharmacokinetic and pharmacodynamic variables', 'The list of pharmacokinetics parameters is listed in Section 9.2.2.1.4.', 'PK exposures (Cmax and AUClast) for alemtuzumab will be determined using noncompartmental', 'analysis. Values will be reported for individual subjects and summarized using descriptive', 'statistics by study week as appropriate.', 'Pharmacodynamic endpoints as described in Section 9.2.2.2 will be summarized using descriptive', 'statistics at each scheduled study visit. Observed measurements as well as change from baseline', 'will be summarized. If a linear trend in the change of a PD endpoint is observed, longitudinal', 'model may be employed to model change from baseline over time. In addition, 95% confidence', 'interval of changes will be presented.', 'Correlation between PD endpoints, biomarkers, efficacy assessments, and exploratory endpoints', 'may be explored as appropriate.', 'Property of the Sanofi Group - strictly confidential', 'Page 88', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '11.4.5 Analyses of exploratory endpoints', 'For the exploratory endpoint of T1 weighted lesion counts, observed measurements will be', 'summarized by visit using descriptive statistics including the number of available observations,', 'mean, SD, median, minimum, and maximum. It may be categorized into different levels and', 'summarized using the number and percentage of patients among the safety population.', 'For the exploratory endpoint of brain volume, observed measurements and change over time from', 'baseline to each postbaseline visit with MRI will be summarized using descriptive statistics', 'including the number of available observations, mean, SD, median, minimum, and maximum.', '11.5 INTERIM ANALYSIS', 'A partial database lock will be done after the last patient has completed efficacy assessments', 'including MRI at the end of Period 2. This database lock will allow comparing brain lesion counts', 'between Period 1 (M-4 to M0) and Period 2 (M4-M8). No formal interim analysis will be', 'performed.', 'Property of the Sanofi Group - strictly confidential', 'Page 89', 'VV-CLIN-0254406: 5.0']\n\n###\n\n", "completion": "END"}